» Articles » PMID: 36296522

Functionalized Ultrasmall Iron Oxide Nanoparticles for -Weighted Magnetic Resonance Imaging of Tumor Hypoxia

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Oct 27
PMID 36296522
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia is a common biological condition in many malignant solid tumors that plays an imperative role in regulating tumor growth and impacting the treatment's therapeutic effect. Therefore, the hypoxia assessment is of great significance in predicting tumor development and evaluating its prognosis. Among the plenty of existing tumor diagnosis techniques, magnetic resonance imaging (MRI) offers certain distinctive features, such as being free of ionizing radiation and providing images with a high spatial resolution. In this study, we develop a fluorescent traceable and hypoxia-sensitive -weighted MRI probe (FeO-Met-Cy5.5) via conjugating notable hypoxia-sensitive metronidazole moiety and Cy5.5 dye with ultrasmall iron oxide (FeO) nanoparticles. The results of in vitro and in vivo experiments show that FeO-Met-Cy5.5 has excellent performance in relaxivity, biocompatibility, and hypoxia specificity. More importantly, the obvious signal enhancement in hypoxic areas indicates that the probe has great feasibility for sensing tumor hypoxia via -weighted MRI. These promising results may unlock the potential of FeO nanoparticles as -weighted contrast agents for the development of clinical hypoxia probes.

Citing Articles

Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials.

Lapusan R, Borlan R, Focsan M Nanoscale Adv. 2024; 6(9):2234-2259.

PMID: 38694462 PMC: 11059564. DOI: 10.1039/d3na01064c.


Molecular imaging of tumour-associated pathological biomarkers with smart nanoprobe: From "Seeing" to "Measuring".

Zhang P, Li W, Liu C, Qin F, Lu Y, Qin M Exploration (Beijing). 2024; 3(6):20230070.

PMID: 38264683 PMC: 10742208. DOI: 10.1002/EXP.20230070.


Designing Smart Iron Oxide Nanoparticles for MR Imaging of Tumors.

Li Z, Bai R, Yi J, Zhou H, Xian J, Chen C Chem Biomed Imaging. 2023; 1(4):315-339.

PMID: 37501794 PMC: 10369497. DOI: 10.1021/cbmi.3c00026.

References
1.
Berezin M, Achilefu S . Fluorescence lifetime measurements and biological imaging. Chem Rev. 2010; 110(5):2641-84. PMC: 2924670. DOI: 10.1021/cr900343z. View

2.
Koukourakis M, Giatromanolaki A, Danielidis V, Sivridis E . Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol. 2007; 84(1):47-52. DOI: 10.1080/09553000701616114. View

3.
Jia Z, Song L, Zang F, Song J, Zhang W, Yan C . Active-target T1-weighted MR Imaging of Tiny Hepatic Tumor via RGD Modified Ultra-small Fe3O4 Nanoprobes. Theranostics. 2016; 6(11):1780-91. PMC: 4997236. DOI: 10.7150/thno.14280. View

4.
Ma T, Zhang P, Hou Y, Ning H, Wang Z, Huang J . "Smart" Nanoprobes for Visualization of Tumor Microenvironments. Adv Healthc Mater. 2018; 7(20):e1800391. DOI: 10.1002/adhm.201800391. View

5.
Vaupel P, Harrison L . Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004; 9 Suppl 5:4-9. DOI: 10.1634/theoncologist.9-90005-4. View